The AUA is challenged with staying fair and relevant to all urologists under the "big tent," even though academic-employed urologists, non-academic-employed urologists, those in private practice, and those in large group practices may have different priorities and problems.
Urologists were taken aback at the ruling, some less so than others, and their responses varied widely at what the law might mean for their practices and the delivery of health care in this country.
Having a positive attitude regarding active surveillance for patients with low-risk prostate cancer does not correlate with the likelihood that radiation oncologists and urologists will recommend it in lieu of treatment.
In just 18 patients, a multicenter phase Ib trial of an intravesical lidocaine-delivery device, called LiRIS (lidocaine-releasing intravesical system), not only knocked down pain and other symptoms for the 2 weeks the device was in the bladders of severely symptomatic patients, but in addition, the effects lasted 4 weeks and longer for many patients.
Urologists use apps on phones and tablets for the benefit of patients and their own convenience.
What does this all mean to the practicing urologist? Here is an overview of what to expect in the months and years ahead.
All-cause and cancer-specific outcomes for Gleason grade 8 and 9 cancers are significantly better than Gleason grade 10 cancer.
Uroplasty, Inc. has announced that EmblemHealth now covers percutaneous tibial nerve stimulation using the company's Urgent PC Neuromodulation System for the treatment of overactive bladder and associated symptoms.
R.D. Levin, MD, has joined Chesapeake Urology Associates and will see patients in the practice's Pine Heights Medical Center and Maple Lawn/Columbia offices in Maryland.
A recently developed genetic test to predict a man's risk for prostate cancer could reduce the need for repeat biopsies in men who have had a negative biopsy, data from a new study indicate.
Many men with prostate cancer do not need immediate treatment, especially if they have low PSA scores or low-risk tumors that are unlikely to grow and spread, according to a multicenter study that suggests such men who undergo radical prostatectomy fare no better than those undergoing observation.
In spite of the record heat wave sweeping much of the nation, now is not the time to cool down. Issues actively being considered in Congress are some of the most vital to urology.
New pediatric urology chiefs have been named at New York-Presbyterian/Morgan Stanley Children's Hospital, New York and the University of Wisconsin, Madison.
Hospitals have virtually given up the search for solo physicians, as a symbol of America's tradition of independent medical practice fades from the scene, a new survey indicates.
Urinary incontinence may be a common problem among young women who have never been pregnant, according to a study in the Annals of Internal Medicine.
Extreme cuts to funding for medical imaging scans in the Medicare fee schedule proposed rule for 2013 are unnecessary, unfounded, and undermine care for the most sick or injure seniors, according to the American College of Radiology.
Physicians should discuss the benefits and risks of PSA testing with their asymptomatic male patients who have life expectancies of greater than 10 years, but the risks outweigh the benefits of men with shorter life expectancies, according to a new evidence-based provisional clinical opinion on prostate cancer screening issued by the American Society of Clinical Oncology.
Loyola University Health System in Maywood, IL has opened a multidisciplinary center to treat women with pelvic floor disorders.
Use of cranberry-containing products appears to be associated with prevention of urinary tract infections in some individuals, according to a meta-analysis published in the Archives of Internal Medicine (2012; 172:988-96).
Older women with acute pyelonephritis can be successfully and safely treated with oral ciprofloxacin (Cipro, Proquin) for 7 days, Swedish researchers report.
The diabetes drug pioglitazone (Actos) was associated with a 22% increased risk of developing bladder cancer in a recent study, supporting earlier research findings of a link between the drug and bladder cancer.
Urologists face a 2% cut in Medicare reimbursement in 2013, according to the recently released 2013 proposed fee schedule from the Centers for Medicare & Medicaid Services.
Male hormonal contraceptives applied daily to the skin appear to reduce sperm production, according to a new study presented at the Endocrine Society annual meeting in Houston.
American Medical Systems (Minnetonka, MN) has signed a co-development agreement with Allergan, Inc. to jointly develop and seek regulatory approval for the delivery of onabotulinumtoxinA (Botox) using the AMS JetTouch system for treatment of overactive bladder.
U.S. Senator Barbara Boxer (D-CA) and Congressman Elijah Cummings (D-MD) recently introduced the Prostate Cancer Detection Research and Education Act, legislation that would improve research and detection of prostate cancer.
A recent study has pinpointed four genes linked to prostate cancer, a finding that researchers say could significantly improve diagnosis and treatment by identifying slow-growing cancers that do not need to be treated and by developing targeted therapies for aggressive forms of the disease.
The FDA has approved the once-daily oral beta-3 adrenergic agonist mirabegron (Myrbetriq) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Scientists at Washington University School of Medicine in St. Louis have found new clues to why some urinary tract infections recur persistently after multiple rounds of treatment.
Testosterone replacement therapy may result in weight reduction and improvement in symptoms of metabolic syndrome, according to separate studies presented at the Endocrine Society annual meeting in Houston.
The FDA recently granted pre-market approval to Prostate Health Index (phi), a noninvasive blood test that manufacturer Beckman Coulter, Inc. claims is 2.5 times more specific in detecting prostate cancer than PSA in patients with PSA values in the 4.0 to 10.0 ng/mL range.